Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Completed · Phase 1

Conditions studied: Non Small Cell Lung Cancer

In brief

This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.

Key facts

Study ID

NCT00456833

Run by

Novartis Pharmaceuticals

People needed

248

Starts

2005-06-01

Last updated by the study team

2020-12-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age over 18 years
• Advanced Non Small Cell Lung Cancer which is not responding to chemotherapy treatment including either cisplatin or carboplatin
• Only 1-2 previous chemotherapy regimens for advanced disease
• More than 2 weeks from previous surgery, radiation or chemotherapy
• Ability to perform normal daily functions

You may not qualify if…

• Chronic steroid treatment
• Prior treatment with EGFR inhibitors
• Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions or other severe medical conditions
• Other cancers within the past 2 years
• Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Atlanta, Georgia, United States
• Novartis Investigative Site — Chicago, Illinois, United States
• Novartis Investigative Site — Boston, Massachusetts, United States
• Novartis Investigative Site — Rochester, Minnesota, United States
• Novartis Investigative Site — Nashville, Tennessee, United States
• Novartis Investigative Site — Houston, Texas, United States
• Novartis Investigative Site — Madison, Wisconsin, United States
• Novartis Investigative Site — Richmond, British Columbia, Canada
• Novartis Investigative Site — Toronto, Ontario, Canada
• Novartis Investigative Site — Montreal, Quebec, Canada
• Novartis Investigative Site — Herlev, Denmark
• Novartis Investigative Site — Saint-Herblain Cédex, France
• Novartis Investigative Site — Villejuif, France
• Novartis Investigative Site — Moscow, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.